Glenmark Pharmaceuticals Limited — Credit Ratings, 19-09-2025: Credit Rating

CRISIL Ratings has revised Glenmark Pharmaceuticals' long-term outlook to 'Positive' from 'Stable', reaffirming the 'CRISIL AA' rating for long-term bank facilities and 'CRISIL A1+' for short-term. This change reflects improved business and financial strength, driven by an exclusive global licensing deal with AbbVie for ISB 2001, which includes an upfront payment of ~₹6,000 crore (USD 700 million).